SEC Form 4 · accession 0001213900-26-069662
NeuroSense Therapeutics Ltd. · NRSN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Or Eisenberg
Officer — Chief Financial Officer
Period of report
Jun 16, 2026
Accepted (ET)
Jun 17, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001875091
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 16, 2026 | P | 250,000 | $0.80 | A | 1,504,050 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On June 16, 2026, the Reporting Person acquired 250,000 ordinary shares, no par value per share, of the Issuer at a purchase price of $0.80 per share, pursuant to a Securities Purchase Agreement dated April 28, 2026, in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.